|
At diagnosis
| | | |
|
Age, years, median (range)
|
53 (18–71)
|
56 (20–75)
|
0.2
|
|
Gender
| | |
0.2
|
|
Male
|
38 (64 %)
|
25 (50 %)
| |
|
Female
|
21 (36 %)
|
25 (50 %)
| |
|
LDH (U/L), median (range)
|
211 (116–928)
|
276.5 (137–1539)
|
0.04
|
|
Extra-nodal site
| | |
0.05
|
|
0
|
7 (12 %)
|
6 (12 %)
| |
|
1
|
49 (83 %)
|
34 (68 %)
| |
|
2
|
3 (5 %)
|
10 (20 %)
| |
|
B symptoms
| | |
0.9
|
|
Yes
|
17 (29 %)
|
15 (30 %)
| |
|
No
|
42 (71 %)
|
35 (70 %)
| |
|
Stage
| | |
<0.001
|
|
I
|
2 (3 %)
|
1 (2 %)
| |
|
II
|
26 (44 %)
|
5 (10 %)
| |
|
III
|
9 (15 %)
|
12 (24 %)
| |
|
IV
|
22 (38 %)
|
32 (64 %)
| |
|
Bone marrow involvement
| | |
0.5
|
|
Yes
|
15 (25 %)
|
16 (32 %)
| |
|
No
|
44 (75 %)
|
34 (68 %)
| |
|
Bulky disease
| | |
0.8
|
|
Yes
|
3 (5 %)
|
6 (6 %)
| |
|
No
|
56 (95 %)
|
47 (94 %)
| |
|
Hemoglobin (g/dl), median (range)
|
12.5 (8.1–13.1)
|
12.5 (6.6–16.9)
|
0.6
|
|
Platelets × 109/l, median (range)
|
231 (14–626)
|
214 (31–719)
|
0.06
|
|
IPI score
| | |
0.01
|
|
0
|
13 (22 %)
|
2 (4 %)
| |
|
1
|
19 (32 %)
|
12 (24 %)
| |
|
2
|
17 (29 %)
|
18 (36 %)
| |
|
3
|
8 (13 %)
|
10 (20 %)
| |
|
4
|
1 (2 %)
|
7 (14 %)
| |
|
5
|
1 (2 %)
|
1 (2 %)
| |
|
Performance status
| | |
0.3
|
|
0
|
7 (12 %)
|
4 (8 %)
| |
|
1
|
45 (76 %)
|
43 (86 %)
| |
|
2
|
5 (8 %)
|
3 (6 %)
| |
|
3
|
2 (45 %)
|
0 (0 %)
| |
|
T-cell lymphoma histologies
| | |
0.9
|
|
Anaplastic large cell
|
10 (17 %)
|
5 (13 %)
| |
|
Angioimmunoblastic
|
15 (25 %)
|
15 (27 %)
| |
|
Enteropathy-associated
|
6 (10 %)
|
3 (6 %)
| |
|
Hepatosplenic
|
1 (2 %)
|
1 (2 %)
| |
|
NK/T
|
7 (12 %)
|
6 (12 %)
| |
|
Panniculitis
|
4 (7 %)
|
3 (6 %)
| |
|
Peripheral
|
16 (27 %)
|
17 (34 %)
| |
|
IPI factors
| | | |
|
Age, years
| | |
0.3
|
|
60
|
18 (31 %)
|
20 (40 %)
| |
|
≤60
|
41 (69 %)
|
30 (60 %)
| |
|
LDH (U/L)
| | |
0.03
|
|
Normal
|
34 (58 %)
|
18 (36 %)
| |
|
Abnormal
|
25 (42 %)
|
32 (64 %)
| |
|
Performance status
| | |
0.3
|
|
1
|
7 (12 %)
|
3 (6 %)
| |
|
≤1
|
52 (88 %)
|
47 (94 %)
| |
|
Extra-nodal disease
| | |
0.02
|
|
1
|
3 (5 %)
|
10 (20 %)
| |
|
≤1
|
56 (95 %)
|
40 (80 %)
| |
|
Stage
| | |
<0.001
|
|
I/II
|
28 (47 %)
|
6 (12 %)
| |
|
III/IV
|
31 (53 %)
|
44 (88 %)
| |
|
IPI index
| | |
0.03
|
|
2
|
10 (17 %)
|
18 (36 %)
| |
|
≤2
|
49 (83 %)
|
32 (64 %)
| |
|
Initial chemotherapy
| | |
0.9
|
|
CHOP
|
58 (98 %)
|
49 (98 %)
| |
|
SMILE
|
1 (2 %)
|
1 (2 %)
| |
|
Salvage chemotherapy (N = 51)
| | |
0.2
|
|
CDE
|
2 (9 %)
|
0 (0 %)
| |
|
DHAP
|
5 (21 %)
|
8 (29 %)
| |
|
ICE
|
16 (70 %)
|
20 (71 %)
| |
|
Up-front transplant
| | |
0.09
|
|
Yes
|
36 (61 %)
|
22 (44 %)
| |
|
No
|
23 (39 %)
|
28 (56 %)
| |
|
At transplant
| | | |
|
Pre-transplant clinical status
| | |
<0.001
|
|
CR
|
51 (86 %)
|
25 (50 %)
| |
|
PR
|
8 (15 %)
|
25 (50 %)
| |
|
Plerixafor
| | |
0.8
|
|
Yes
|
21 (36 %)
|
19 (38 %)
| |
|
No
|
38 (64 %)
|
31 (62 %)
| |
|
Infused CD34, median (range)
|
5.42 (2.25–13.44)
|
5.12 (2.04–15.65)
|
0.9
|
|
Number of collections
| | |
0.08
|
|
1
|
7 (12 %)
|
12 (24 %)
| |
|
2
|
19 (32 %)
|
15 (30 %)
| |
|
3
|
19 (32 %)
|
9 (18 %)
| |
|
4
|
7 (12 %)
|
11 (22 %)
| |
|
5
|
1 (2 %)
|
2 (4 %)
| |
|
6
|
3 (5 %)
|
0 (0 %)
| |
|
7
|
2 (3 %)
|
0 (0 %)
| |
|
8
|
1 (2 %)
|
1 (2 %)
| |
|
A-ALC, median (range)
|
0.68 (0.21–3.83)
|
0.44 (0.06–1.40)
|
<0.001
|
|
A-AMC, median (range)
|
0.45 (0.10–1.42)
|
0.78 (0.20–1.60)
|
<0.001
|
|
ALC-15, median (range)
|
0.71 (0.10–2.31)
|
0.41 (0.10–1.18)
|
<0.001
|
|
AMC-15, median (range)
|
0.43 (0.04–1.19)
|
0.90 (0.20–2.31)
|
<0.001
|
|
LMR-15
|
1.71 (0.24–15.5)
|
0.57 (0.08–3.18)
|
<0.001
|
